tetano
Editor, Senior Moderator
J Clin Virol
. 2023 Dec 13:170:105634.
doi: 10.1016/j.jcv.2023.105634. Online ahead of print. The diagnostic accuracy of the ID NOW COVID-19 point of care test in acute hospital admissions
Ameeka Thompson[SUP] 1 [/SUP], David Hettle[SUP] 2 [/SUP], Stephanie Hutchings[SUP] 3 [/SUP], Barry Vipond[SUP] 3 [/SUP], Nicholas Veasey[SUP] 4 [/SUP], Kerry Grant[SUP] 5 [/SUP], Jonathan Turner[SUP] 3 [/SUP], Rich Hopes[SUP] 3 [/SUP], Jonathan Steer[SUP] 3 [/SUP], Rommel Ravanan[SUP] 6 [/SUP], O Martin Williams[SUP] 7 [/SUP], Peter Muir[SUP] 3 [/SUP]
Affiliations
Background: Prompt identification of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection on admission to hospital is crucial to ensuring initiation of appropriate treatment, optimising infection control and maintaining patient flow. The Abbott ID NOW™ COVID-19 assay (ID NOW) is a point-of-care, isothermal nucleic acid amplification test, capable of producing a result within minutes, potentially placing it as an invaluable tool in helping to control the coronavirus-disease 2019 (COVID-19) pandemic.
Objectives: To evaluate the diagnostic accuracy of ID NOW in acute hospital admissions.
Study design: A prospective approach to data collection was undertaken in consecutive patients with ID NOW and Hologic Aptima™ SARS-CoV-2 transcription-mediated amplification assay (Aptima TMA) results, across three hospitals in the south-west of England between 1st March and 30th September 2021. A nasal swab was taken for ID NOW and a combined nose and throat swab for Aptima TMA. Measures of diagnostic accuracy were calculated for ID NOW against Aptima TMA. This study was conducted during a period of alpha and delta strain predominance.
Results: 19,698 ID NOW assays were performed, of which 12,821 had an Aptima TMA assay performed within 24 hours. ID NOW had sensitivity of 85.2 % (95 % CI, 82.2-87.9) and specificity of 99.6 % (95 % CI, 99.4-99.7) compared with the reference assay. The overall PPV was 91.0 % (95 % CI, 88.5-93.0) and the overall NPV was 99.3 % (95 % CI, 99.1-99.4).
Conclusions: ID NOW offers a valid diagnostic tool to detect SARS-CoV-2, performing comparably to a reference laboratory-based assay which takes longer to provide results.
Keywords: COVID-19; ID NOW; Point-of-care testing; SARS-CoV-2.
. 2023 Dec 13:170:105634.
doi: 10.1016/j.jcv.2023.105634. Online ahead of print. The diagnostic accuracy of the ID NOW COVID-19 point of care test in acute hospital admissions
Ameeka Thompson[SUP] 1 [/SUP], David Hettle[SUP] 2 [/SUP], Stephanie Hutchings[SUP] 3 [/SUP], Barry Vipond[SUP] 3 [/SUP], Nicholas Veasey[SUP] 4 [/SUP], Kerry Grant[SUP] 5 [/SUP], Jonathan Turner[SUP] 3 [/SUP], Rich Hopes[SUP] 3 [/SUP], Jonathan Steer[SUP] 3 [/SUP], Rommel Ravanan[SUP] 6 [/SUP], O Martin Williams[SUP] 7 [/SUP], Peter Muir[SUP] 3 [/SUP]
Affiliations
- PMID: 38211537
- DOI: 10.1016/j.jcv.2023.105634
Background: Prompt identification of patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection on admission to hospital is crucial to ensuring initiation of appropriate treatment, optimising infection control and maintaining patient flow. The Abbott ID NOW™ COVID-19 assay (ID NOW) is a point-of-care, isothermal nucleic acid amplification test, capable of producing a result within minutes, potentially placing it as an invaluable tool in helping to control the coronavirus-disease 2019 (COVID-19) pandemic.
Objectives: To evaluate the diagnostic accuracy of ID NOW in acute hospital admissions.
Study design: A prospective approach to data collection was undertaken in consecutive patients with ID NOW and Hologic Aptima™ SARS-CoV-2 transcription-mediated amplification assay (Aptima TMA) results, across three hospitals in the south-west of England between 1st March and 30th September 2021. A nasal swab was taken for ID NOW and a combined nose and throat swab for Aptima TMA. Measures of diagnostic accuracy were calculated for ID NOW against Aptima TMA. This study was conducted during a period of alpha and delta strain predominance.
Results: 19,698 ID NOW assays were performed, of which 12,821 had an Aptima TMA assay performed within 24 hours. ID NOW had sensitivity of 85.2 % (95 % CI, 82.2-87.9) and specificity of 99.6 % (95 % CI, 99.4-99.7) compared with the reference assay. The overall PPV was 91.0 % (95 % CI, 88.5-93.0) and the overall NPV was 99.3 % (95 % CI, 99.1-99.4).
Conclusions: ID NOW offers a valid diagnostic tool to detect SARS-CoV-2, performing comparably to a reference laboratory-based assay which takes longer to provide results.
Keywords: COVID-19; ID NOW; Point-of-care testing; SARS-CoV-2.